Camp4 Therapeutics (CAMP) EBITDA (2023 - 2026)

Camp4 Therapeutics has disclosed EBITDA across 4 years of filings, most recently posting -$18.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$18.3 million, down 47.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.3 million (down 66.69% YoY), and the FY2025 annual result was -$80.4 million, down 55.25% from the prior year.
• EBITDA came in at -$18.3 million for Q1 2026 at Camp4 Therapeutics, up from -$40.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$11.7 million in Q3 2023 to a low of -$40.3 million in Q4 2025.
• The 4-year median for EBITDA is -$13.0 million (2023), against an average of -$15.9 million.
• Peak annual rise in EBITDA reached 0.15% in 2025, while the deepest fall reached 203.37% in 2025.
• Camp4 Therapeutics' EBITDA stood at -$13.0 million in 2023, then retreated by 2.22% to -$13.3 million in 2024, then tumbled by 203.37% to -$40.3 million in 2025, then surged by 54.5% to -$18.3 million in 2026.
• The last three EBITDA figures came in at -$18.3 million (Q1 2026), -$40.3 million (Q4 2025), and -$15.1 million (Q3 2025), per Business Quant data.